News Releases

Date	Title	Additional Formats
October 19, 2026	Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
October 12, 2026	Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
October 8, 2026	Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
September 29, 2026	Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
September 1, 2026	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
July 30, 2026	Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
July 20, 2026	Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
June 23, 2026	Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
May 22, 2026	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 20, 2026	Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting